Proton Radiation for Chordomas and Chondrosarcomas
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01449149 |
Recruitment Status :
Active, not recruiting
First Posted : October 10, 2011
Last Update Posted : June 22, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chordomas Chondrosarcomas | Radiation: Proton Therapy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Proton Radiation For Chordomas and Chondrosarcomas |
Actual Study Start Date : | March 2010 |
Estimated Primary Completion Date : | December 2026 |
Estimated Study Completion Date : | December 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Proton group
Proton radiation total dose 72.00 to 79.2 Gy(RBE) in 40-44 fractions
|
Radiation: Proton Therapy |
- Feasibility of proton RT for chordomas and chondrosarcomas [ Time Frame: Up to 10 days ]Treatment completion
- Acute Toxicity [ Time Frame: 90 days ]Any grade 3 or higher toxicity observed within 90 days from start of therapy.
- Late toxicity [ Time Frame: 90 days ]Any grade 3 or higher toxicty observed later than 90 days from completion of therapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed diagnosis of chordoma or chondrosarcoma.
- Patients must have no evidence of metastatic disease based on routine imaging (CT or MRI of the chest/abdomen/pelvis, bone scan, etc.)
- Patients must have an ECOG score equal to or less than 2.
- Age ≥ 18 years.
- Patients must be able to provide informed consent.
- Adequate bone marrow function: WBC ≥ 4000/mm3, platelets ≥ 100, 000mm3
- Women of child-bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive , IUD, condoms or other barrier methods etc.) Hysterectomy or menopause must be clinically documented.
- Tumors arising in the skull and spine.
Exclusion Criteria:
- Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)
- Patients with the following histologies are excluded: melanoma , other soft tissue or bony sarcomas, giant cell tumor aneurismal bone cyst or metastatic lesions from other histologies.
- Pregnant women.
- Actively being treated on any other therapeutic research study.
- Tumors arising outside of the CNS.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01449149
United States, Pennsylvania | |
Abramson Cancer Center of the University of Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104 |
Responsible Party: | Abramson Cancer Center at Penn Medicine |
ClinicalTrials.gov Identifier: | NCT01449149 |
Other Study ID Numbers: |
UPCC 01310 |
First Posted: | October 10, 2011 Key Record Dates |
Last Update Posted: | June 22, 2023 |
Last Verified: | June 2023 |
Age 18 or greater No prior radiation |
Chondrosarcoma Chordoma Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue |
Neoplasms by Histologic Type Neoplasms Sarcoma Neoplasms, Germ Cell and Embryonal |